Clinical medicine profile
Anti-D immunoglobulin
Vaccine / immunological product
- Route
- IM / SC / ORAL / ID
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Anaphylaxis to prior dose or component.
- Live vaccines contraindicated in significant immunosuppression and usually pregnancy.
- Defer for moderate–severe acute illness.
Precautions
- Observe 15 minutes post-dose if high anaphylaxis concern.
- Correct injection technique and site.
- Report AEFI via national systems.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Full-term Delivery: 300 ug within 72 hrs of delivery (e.g. birth, abortion) if there are no pre-existing anti-D antibodies. (It can still be administered even if a longer period has elapsed). Prophylactic doses of 300ug on 28th and 34th weeks of gestation and 300ug within 72 hrs of delivery for the un-sensitized patients. For transplacental bleed in excess of 4-5ml fetal red cells: administer 60 -75 ug per ml fetal red cells. For stillbirth, abortion, amniocentesis and other sensitizing episodes up to 20 wks gestation: 150 ug per episode within 72 hrs. In case of incompatible blood transfusion: 75 ug / ml of transfused Rh (+ve) blood.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
N/A generally.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
N/A generally.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Vaccine / immunological product).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Prophylaxis of Rhesus sensitization.
Adverse effects
- Local pain, low-grade fever, myalgia.
- Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
Drug interactions
Open multi-drug checker ↗- Over 90% of Rh (-ve) women having Rh (+ve) offspring do not form anti-D antibodies.
- As it is not possible to predict who will make antibodies, all Rh(-ve) women with an Rh(+ve) baby must be given prophylaxis.Since Rh antigens are detectable in an embryo a few weeks after conception, anti-D immunoglobulin should also be given to Rh(-ve) women who have aborted.
Mechanism & disposition
The mechanism of inhibition of anti-body synthesis is unclear, but rapid destruction and clearance of Rh-positive cells from the circulation seem to play a role.
Read complete mechanism
The mechanism of inhibition of anti-body synthesis is unclear, but rapid destruction and clearance of Rh-positive cells from the circulation seem to play a role.
Immune response days–weeks
Months–lifelong (schedule-dependent)
IM / SC / ORAL / ID
Pregnancy, lactation & diet
Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.
Most vaccines compatible; live vaccines usually fine for breastfeeding mother.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.